ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Johnson & Johnson’s Janssen Pharmaceuticals unit has agreed to license hepatitis C drug assets from Achillion Pharmaceuticals, a developer of small-molecule drugs for infectious diseases. Janssen will invest $225 million in Achillion stock plus up to $1.1 billion in potential development, regulatory, and sales milestone payments. Achillion’s lead compound, ACH-3102, is a second-generation NS5A inhibitor now in Phase II clinical trials. J&J already markets the older treatment Olysio, but the firm isn’t a player in the newer all-oral market.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X